AAAAAA
Results: 1-25/68
Authors:
Lincoff, AM
Citation: Am. Lincoff, Anticoagulant and antiplatelet drugs, CATHET C IN, 54(4), 2001, pp. 514-520
Authors:
L'Allier, PL
Lincoff, AM
Citation: Pl. L'Allier et Am. Lincoff, Platelet glycoprotein IIb/IIIa inhibitors combined with fibrinolytic agents to treat acute myocardial infarction, J THROMB TH, 11(1), 2001, pp. 83-91
Authors:
Wang, K
Zhou, ZM
Zhou, XR
Tarakji, K
Topol, EJ
Lincoff, AM
Citation: K. Wang et al., Prevention of intimal hyperplasia with recombinant soluble P-selectin glycoprotein ligand-immunoglobulin in the porcine coronary artery balloon injury model, J AM COL C, 38(2), 2001, pp. 577-582
Authors:
Greenbaum, AB
Harrington, RA
Hudson, MP
MacAulay, CM
Wilcox, RG
Simoons, ML
Berdan, LG
Guerci, A
Cokkinos, DV
Kitt, MM
Lincoff, AM
Topol, EJ
Califf, RM
Ohman, EM
Citation: Ab. Greenbaum et al., Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes, J AM COL C, 37(2), 2001, pp. 492-498
Authors:
Topol, EJ
Califf, RM
Van de Werf, F
Willerson, JT
Booth, J
White, H
Clayman, M
Deckelbaum, L
Lincoff, AM
Ohman, EM
Bates, E
Gibler, WB
Hochman, J
Kleiman, N
Grinfeld, L
Aylward, P
Armstrong, PW
Heikkila, J
Vahanian, A
Steg, G
Bode, C
Adgy, AAJ
Guetta, V
Ardissino, D
Savonitto, S
Bar, F
Simoons, M
Kontny, F
White, H
Sadowski, Z
Seabra-Gomes, R
Dalby, A
Betriu, A
Swahn, E
Wilcox, R
Frye, RL
Bertrand, ME
DeMets, D
Fox, KKA
Fuster, V
Lee, KL
McCarthy, C
Waller, M
Scherer, J
van de Kerkhove, A
Kukulewicz, L
Booth, JE
Del Valle, M
Hibert, D
Brannon, D
Citation: Ej. Topol et al., Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO randomised trial, LANCET, 357(9272), 2001, pp. 1905-1914
Authors:
Aronow, HD
Topol, EJ
Roe, MT
Houghtaling, PL
Wolski, KE
Lincoff, AM
Harrington, RA
Califf, RM
Ohman, EM
Kleiman, NS
Keltai, M
Wilcox, RG
Vahanian, A
Armstrong, PW
Lauer, MS
Citation: Hd. Aronow et al., Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study, LANCET, 357(9262), 2001, pp. 1063-1068
Authors:
Akkerhuis, KM
Deckers, JW
Lincoff, AM
Tcheng, JE
Boersma, E
Anderson, K
Balog, C
Califf, RM
Topol, EJ
Simoons, ML
Citation: Km. Akkerhuis et al., Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention, J AM MED A, 286(1), 2001, pp. 78-82
Authors:
Tcheng, JE
Kereiakes, DJ
Lincoff, AM
George, BS
Kleiman, NS
Sane, DC
Cines, DB
Jordan, RE
Mascelli, MA
Langrall, MA
Damaraju, L
Schantz, A
Effron, MB
Braden, GA
Citation: Je. Tcheng et al., Abciximab readministration - Results of the ReoPro readministration registry, CIRCULATION, 104(8), 2001, pp. 870-875
Authors:
Park, SH
Marso, SP
Zhou, ZM
Foroudi, F
Topol, EJ
Lincoff, AM
Citation: Sh. Park et al., Neointimal hyperplasia after arterial injury is increased in a rat model of non-insulin-dependent diabetes mellitus, CIRCULATION, 104(7), 2001, pp. 815-819
Authors:
Tardiff, BE
Jennings, LK
Harrington, RA
Gretler, D
Potthoff, RF
Vorchheimer, DA
Eisenberg, PR
Lincoff, AM
Labinaz, M
Joseph, DM
McDougal, MF
Kleiman, NS
Citation: Be. Tardiff et al., Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes - Prospective analysis from PURSUIT, CIRCULATION, 104(4), 2001, pp. 399-405
Authors:
Lauer, MA
Houghtaling, PL
Peterson, JG
Granger, CB
Bhatt, DL
Sapp, SK
Simoons, ML
Harrington, RA
Topol, EJ
Lincoff, AM
Citation: Ma. Lauer et al., Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acutecoronary syndromes - Observations from the platelet IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial, CIRCULATION, 104(23), 2001, pp. 2772-2777
Authors:
Chew, DP
Bhatt, DL
Lincoff, AM
Moliterno, DJ
Brener, SJ
Wolski, KE
Topol, EJ
Citation: Dp. Chew et al., Defining the optimal activated clotting times during percutaneous coronaryintervention: Aggregate results from 6 randomized, controlled trials - Response, CIRCULATION, 104(22), 2001, pp. E124-E124
Authors:
Ellis, SG
Brener, SJ
Lincoff, AM
Moliterno, DJ
Whitloe, PL
Schneider, JP
Citation: Sg. Ellis et al., beta-blockers before percutaneous coronary intervention do not attenuate postprocedural creatine kinase isoenzyme rise, CIRCULATION, 104(22), 2001, pp. 2685-2688
Authors:
Lincoff, AM
Kereiakes, DJ
Mascelli, MA
Deckelbaum, LI
Barnathan, ES
Patel, KK
Frederick, B
Nakada, MT
Topol, EJ
Citation: Am. Lincoff et al., Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization, CIRCULATION, 104(2), 2001, pp. 163-167
Authors:
Chew, DP
Bhatt, DL
Lincoff, AM
Moliterno, DJ
Brener, SJ
Wolski, KE
Topol, EJ
Citation: Dp. Chew et al., Optimal activated clotting time during percutaneous coronary intervention - Response, CIRCULATION, 104(15), 2001, pp. E83-E84
Authors:
Chew, DP
Bhatt, DL
Lincoff, AM
Moliterno, DJ
Brener, SJ
Wolski, KE
Topol, EJ
Citation: Dp. Chew et al., Defining the optimal activated clotting time during percutaneous coronary intervention - Aggregate results from 6 randomized, controlled trials, CIRCULATION, 103(7), 2001, pp. 961-966
Authors:
Steinhubl, SR
Talley, JD
Braden, GA
Tcheng, JE
Casterella, PJ
Moliterno, DJ
Navetta, FI
Berger, PB
Popma, JJ
Dangas, G
Gallo, R
Sane, DC
Saucedo, JF
Jia, G
Lincoff, AM
Theroux, P
Holmes, DR
Teirstein, PS
Kereiakes, DJ
Citation: Sr. Steinhubl et al., Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention - Results of the GOLD (AU-Assessing Ultegra) multicenter study, CIRCULATION, 103(21), 2001, pp. 2572-2578
Authors:
Steinhubl, SR
Ellis, SG
Wolski, K
Lincoff, AM
Topol, EJ
Citation: Sr. Steinhubl et al., Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events - Data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) trial, CIRCULATION, 103(10), 2001, pp. 1403-1409
Authors:
Tcheng, JE
Talley, JD
O'Shea, JC
Gilchrist, IC
Kleiman, NS
Grines, CL
Davidson, CJ
Lincoff, AM
Califf, RM
Jennings, LK
Kitt, MM
Lorenz, TJ
Citation: Je. Tcheng et al., Clinical pharmacology of higher dose eptifibatide in percutaneous coronaryintervention (the PRIDE study), AM J CARD, 88(10), 2001, pp. 1097-1102
Authors:
Peterson, JG
Topol, EJ
Roe, MT
Sapp, SK
Lincoff, AM
Deckers, JW
Blackstone, EH
Harrington, RA
Califf, RM
Lauer, MS
Citation: Jg. Peterson et al., Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes, AM J CARD, 87(5), 2001, pp. 532-536
Authors:
L'Allier, PL
Lincoff, AM
Citation: Pl. L'Allier et Am. Lincoff, Early invasive versus early conservative strategies for acute coronary syndromes, ACUTE CORONARY SYNDROMES, SECOND EDITION, 2001, pp. 391-417
Authors:
Roe, MT
Sapp, SK
Lincoff, AM
Citation: Mt. Roe et al., Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes, CLEV CLIN J, 67(2), 2000, pp. 131-140
Authors:
Herrmann, HC
Moliterno, DJ
Ohman, EM
Stebbins, AL
Bode, C
Betriu, A
Forycki, F
Miklin, JS
Bachinsky, WB
Lincoff, AM
Califf, RM
Topol, EJ
Citation: Hc. Herrmann et al., Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction - Results from the SPEED (GUSTO-4 pilot) trial, J AM COL C, 36(5), 2000, pp. 1489-1496
Authors:
Lincoff, AM
Citation: Am. Lincoff, First clinical investigation of a tissue-factor inhibitor administered during percutaneous coronary revascularization: A randomized, double-blinded, dose-escalation trial - Assessing safety and efficacy of FFR-FVIIa in percutaneous transluminal coronary angioplasty (ASIS) trial, J AM COL C, 36(1), 2000, pp. 312-313
Authors:
Lincoff, AM
Califf, RM
Topol, EJ
Citation: Am. Lincoff et al., Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease, J AM COL C, 35(5), 2000, pp. 1103-1115